Replies to post #217666 on Biotech Values

[jbog]

I think what's hurting Revance somewhat is that they don't expect to file, nor will they be on the market for a long time. I don't know why they are delaying the filing until next year with approval not expected before 2020?

Is there a reason?

[marthambles]

IMO the Mylan deal is a net positive if you believe a biosimilar would have entered the market in any event.

[DewDiligence]

RVNC implements $125M ATM with Cantor Fitzgerald:

https://twitter.com/DewDiligence/status/973661398302674944

https://www.sec.gov/Archives/edgar/data/1479290/000119312518080738/d532149d424b5.htm

[DewDiligence]

Top-5 non-invasive cosmetic procedures in US (2017):

• Botulinum toxin: 7.2M
• Dermal fillers: 2.7M
• Chemical peel: 1.4M
• Laser hair removal: 1.1M
• Microdermabrasion: 0.7M

The RoW proportions are roughly similar.

https://www.plasticsurgery.org/news/press-releases/new-statistics-reveal-the-shape-of-plastic-surgery

[DewDiligence]

RVNC—Management hires include AGN’s head of international commercial operations:

https://www.businesswire.com/news/home/20180402005685/en/

Revance Therapeutics…today announced the appointments of Dustin Sjuts as Vice President of Strategy and Sales, Aesthetic and Therapeutic; Ben Putman as Vice President of Digital; and Marc Korenberg as Senior Director of Commercial Operations. In addition, Erica Bazerkanian has been promoted to Vice President of Marketing, Aesthetics and Therapeutics.

All four positions are newly established and will report to Todd Zavodnick, Chief Commercial Officer and President, Aesthetics & Therapeutics, who leads the company’s commercial operations and launch preparations for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar (frown) lines.

In his new role at Revance, Mr. Sjuts will head all product sales activities, championing strategies to enhance physician relations and drive new product adoption. Most recently, he held leadership positions at Nestle Skin Health, including Business Unit Head in China and Senior Director of Marketing in the U.S. In China, he was responsible for the medical aesthetics commercial organization, leading the development and execution of the medical solutions strategy. Prior to this, Mr. Sjuts was Senior Vice President of Franchise Operations for Alphaeon. Previously, he served as Director of Sales in Eye Care and as Senior Regional Manager of Aesthetics at Allergan.

…In his new role, Mr. Korenberg will manage commercial operations activities at Revance, including customer excellence and relationship management, commercial analytics, commercial programs, and commercial financial management. Most recently, he was Director of Commercial, International at Allergan, after the acquisition of Zeltiq Aesthetics, Inc., where Marc served as the Director of International Finance and Operations.